Compound: zaleplon
SMILES: O=C(N(c1cc(-c2n3ncc(c3ncc2)C#N)ccc1)CC)C
InChIKey: HUNXMJYCHXQEGX-UHFFFAOYSA-N
Synonyms: zaleplon, Sonata, 151319-34-5, CL-284846, SKP-1041, ZAL-846, CL 284,846, Zaleplon civ, L846, LJC-10846, CL 284846, N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide, L-846, zaleplone, 3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide, S62U433RMH, DTXSID5023748, N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide, LJC10846, 3'-(3-Cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)-N-ethylacetanilide, DTXCID103748, CHEBI:10102, Acetamide, N-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethyl-, N-(3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl)-N-ethylacetamide, N-(3-{3-cyanopyrazolo[1,5-a]pyrimidin-7-yl}phenyl)-N-ethylacetamide, Acetamide, N-(3-(3-cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)phenyl)-N-ethyl-, CL284,846, zaleplonum, RefChem:58218, N05CF03, LJC 10846, DEA No. 2781, NCGC00160525-01, ZAL 846, Staccato-zaleplon, SMR000238180, Sonata (TN), CAS-151319-34-5, UNII-S62U433RMH, Zaleplon AP, Zaleplon [USAN:USP:INN:BAN], AZ-007, ZALEPLON [USAN], ZALEPLON [INN], ZALEPLON [JAN], ZALEPLON [MI], ZALEPLON [VANDF], N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl-acetamide, ZALEPLON [MART.], ZALEPLON [WHO-DD], Zaleplon (JAN/USP/INN), CHEMBL1521, ZALEPLON [EMA EPAR], SCHEMBL29118, MLS000759451, MLS001424238, BIDD:GT0046, Zaleplon, 1mg/ml in Methanol, ZALEPLON [ORANGE BOOK], ZALEPLON CIV [USP-RS], GTPL4345, SCHEMBL29375436, ZALEPLON [USP MONOGRAPH], BDBM86521, Zaleplon 1.0 mg/ml in Methanol, HMS2052J11, HMS3394J11, HMS3713H08, CAS_5719, NSC_5719, Tox21_111872, MFCD00867990, Zaleplon, >=98% (HPLC), solid, AKOS000280863, Tox21_111872_1, AC-2082, CCG-101187, DB00962, NC00437, SS-4571, NCGC00160525-02, HY-14265, DB-015068, NS00006819, C07484, D00530, Z-0500, AB00640003_03, Q145052, SR-01000759426, SR-01000759426-3, BRD-K92657060-001-05-7, Zaleplon, United States Pharmacopeia (USP) Reference Standard, 3'-(3-CYANOPYRAZOLO(1,5-.ALPHA.)PYRIMIDIN-7-YL)-N-ETHYLACETANILIDE, N-[3-(3-cyano-7-pyrazolo[1,5-a]pyrimidinyl)phenyl]-N-ethylacetamide, N-[3-(3-cyanopyrazolo-[1,5-a]-pyrimidin-7-yl)-phenyl]-N-ethyl acetamide, ACETAMIDE, N-(3-(3-CYANOPYRAZOLO(1,5-.ALPHA.)PYRIMIDIN-7-YL)PHENYL)-N-ETHYL-, 1007130-22-4
Theoretical properties:
molecular_formula: C17H15N5O
molecular_weight: 305.33 g/mol
exact_mass: 305.12766012 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 0
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 3
heavy_atom_count: 23
topological_polar_surface_area: 74.3 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 157-159 °C
solubility: 4.03e-02 g/L
Descriptions:
pubchem: Zaleplon is a pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position. It has a role as an anxiolytic drug, a central nervous system depressant, an anticonvulsant and a sedative. It is a nitrile and a pyrazolopyrimidine.
chebi: A pyrazolo[1,5-<em>a</em>]pyrimidine having a nitrile group at position 3 and a 3-(<em>N</em>-ethylacetamido)phenyl substituent at the 7-position.
chembl: ZALEPLON is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Zaleplon, sold under the brand name Sonata among others, is a sedative and hypnotic which is used to treat insomnia. It is a nonbenzodiazepine or Z-drug of the pyrazolopyrimidine class. It was developed by King Pharmaceuticals and approved for medical use in the United States in 1999.